The Barrier–Microbiota–Inflammation Axis in Colorectal Cancer: Mechanisms and Emerging Diagnostic & Therapeutic Strategies
Cancers · 10.02.2026 · 18 (4) · 576
DOI: 10.3390/cancers18040576 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 10.02.2026. Verfasst von Xuanchi Dong und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Surgery, Central Hospital of Dalian University of Technology (Dalian Municipal Central Hospital), Dalian 116021, China. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 173 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Fok Ying Tung Education Foundation, State Key Laboratory of Fine Chemicals.
Abstract (Originalsprache)
Colorectal cancer (CRC) is a leading cause of global cancer incidence and mortality, with rising prevalence among younger individuals. Accumulating evidence reveals a critical pathological axis linking intestinal barrier disruption, gut microbial dysbiosis, and chronic inflammation, collectively driving CRC initiation. Early colorectal lesions exhibit microbial shifts—reduced α-diversity with clear β-diversity separation, enrichment of oral-origin/pathobiont taxa and depletion of butyrate producers—alongside impaired mucus and tight junction integrity. Concurrent chemical barrier drifts, with decreased short-chain fatty acids and increased secondary bile acids, enhance epithelial stress and vulnerability. The resultant permeability facilitates the translocation of microbial products, triggering inflammation and tumorigenesis. This paper focuses on a review of the relationship between gut microbiota, intestinal barrier, inflammatory signaling pathways, and tumor initiation, sorting out its potential role in developing, diagnosing, and treating CRC. Collectively, this cascade axis offers theoretical and empirical support for the early pathological detection and intervention of CRC, indicating promising directions for future precision screening and stratified management strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastrointestinal Surgery, Central Hospital of Dalian University of Technology (Dalian Municipal Central Hospital), Dalian 116021, China.
- Cancer Hospital of Dalian University of Technology, State Key Laboratory of Fine Chemicals, Dalian R&D Center for Stem Cell and Tissue Engineering, Dalian University of Technology, Dalian 116024, China.
- Rehabilitation College, Affiliated Rehabilitation Hospital, Jiangxi Medical College, Nanchang University, Nanchang 330003, China.
ORCID-Profile: Jie Xu
Förderung
- National Natural Science Foundation of China
- Fok Ying Tung Education Foundation
- State Key Laboratory of Fine Chemicals
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Dong, X., Yang, J., He, L., Fang, H., Wang, L., Zhu, J., Xu, J., Song, K., & Xuan, Z. (2026). The Barrier–Microbiota–Inflammation Axis in Colorectal Cancer: Mechanisms and Emerging Diagnostic & Therapeutic Strategies. Cancers, 18(4), 576. https://doi.org/10.3390/cancers18040576
Vancouver
Dong X, Yang J, He L, Fang H, Wang L, Zhu J, et al. The Barrier–Microbiota–Inflammation Axis in Colorectal Cancer: Mechanisms and Emerging Diagnostic & Therapeutic Strategies. Cancers. 2026;18(4):576. doi:10.3390/cancers18040576
BibTeX
@article{Dong2026,
author = {Dong, Xuanchi and Yang, Ji and He, Langyu and Fang, Huan and Wang, Lei and Zhu, Jingjing and Xu, Jie and Song, Kedong and Xuan, Zhiqiang},
title = {The Barrier–Microbiota–Inflammation Axis in Colorectal Cancer: Mechanisms and Emerging Diagnostic & Therapeutic Strategies},
journal = {Cancers},
year = {2026},
volume = {18},
number = {4},
pages = {576},
doi = {10.3390/cancers18040576}
}
EUVIMED